Roche disclosed mid-stage clinical data for a daily incretin shot in type 1 diabetes, a disease state where GLP-1-based drugs are not typically viewed as a direct solution. The company’s Phase 2 results were highlighted in the context of an unmet need for insulin-independent or insulin-reducing approaches. The update signals Roche’s effort to broaden the therapeutic footprint of its incretin platforms beyond obesity and type 2 diabetes, using endocrine pathway modulation to target hyperglycemia drivers in type 1. For the broader market, it underscores that incretin developers are actively testing adjacent biology across diabetes categories rather than limiting claims to established type 2 mechanisms.